{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:13:06Z","timestamp":1776769986913,"version":"3.51.2"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T00:00:00Z","timestamp":1460592000000},"content-version":"vor","delay-in-days":1079,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ihj.2013.04.019","type":"journal-article","created":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T21:30:39Z","timestamp":1365543039000},"page":"250-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Epidemiology of cardioprotective pharmacological agent use in stable coronary heart disease"],"prefix":"10.1016","volume":"65","author":[{"given":"Krishna Kumar","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukul","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soneil","family":"Guptha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeeb","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.S.","family":"Khedar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishant","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2013.04.019_bib1","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/archinte.162.21.2405","article-title":"The underlying risk of death after myocardial infarction in the absence of treatment","volume":"162","author":"Law","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ihj.2013.04.019_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(02)09358-3","article-title":"Two decades of progress in preventing vascular disease","volume":"360","author":"Yusuf","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.04.019_bib3","first-page":"149","article-title":"ACC\/AHA 2002 guideline update for the management of patients with chronic stable angina","volume":"107","author":"Gibbons","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.04.019_bib4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","article-title":"European guidelines on cardiovascular disease prevention in clinical practice","volume":"28","author":"Graham","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2013.04.019_bib5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJMra001529","article-title":"Cardiac rehabilitation and secondary prevention of coronary heart disease","volume":"345","author":"Ades","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.04.019_bib6","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.04.019_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ihj.2013.04.019_bib8","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double- blind, placebo-controlled, multicentre trial","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.04.019_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ihj.2013.04.019_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.pcad.2009.01.001","article-title":"Clinical insights from the Treating to New Targets trial","volume":"51","author":"Waters","year":"2009","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ihj.2013.04.019_bib11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archinternmed.2010.189","article-title":"By Jove! what is a clinician to make of JUPITER?","volume":"170","author":"Kaul","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ihj.2013.04.019_bib12","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.jacc.2003.12.043","article-title":"From knowledge to practice in chronic cardiovascular disease: a long and winding road","volume":"43","author":"Majumdar","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.04.019_bib13","first-page":"1007","article-title":"Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India","volume":"5","author":"Sharma","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ihj.2013.04.019_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccl.2010.11.001","article-title":"Role of medical versus interventional strategies to prevent coronary events in patients with stable coronary artery disease","volume":"29","author":"Carbajal","year":"2011","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.ihj.2013.04.019_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehab"},{"key":"10.1016\/j.ihj.2013.04.019_bib16","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","article-title":"Three year follow-up and event rates in the international REACH registry","volume":"30","author":"Alberts","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2013.04.019_bib17","first-page":"820","article-title":"WHO study on prevention of recurrences of myocardial infarction and stroke","volume":"83","author":"Mendis","year":"2005","journal-title":"Bull WHO"},{"key":"10.1016\/j.ihj.2013.04.019_bib18","unstructured":"ORG-IMS. IMS India pharmaceutical audit. Available at: http:\/\/www.imshealth.co.in\/images\/pdf\/sales%20audits%20-%20introduction%20%26%20methodology.pdf."},{"key":"10.1016\/j.ihj.2013.04.019_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncpcardio1419","article-title":"Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population","volume":"6","author":"Sanz","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.ihj.2013.04.019_bib20","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1503\/cmaj.081913","article-title":"Long-term trends and use of and expenditures for cardiovascular medications in Canada","volume":"181","author":"Jackevicius","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.ihj.2013.04.019_bib21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1136\/bmj.329.7473.1013","article-title":"Evidence based guidelines or collectively constructed \u201cmindlines?\u201d Ethnographic study of knowledge management in primary care","volume":"329","author":"Gabbay","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.ihj.2013.04.019_bib22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.04.019_bib23","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1161\/CIRCULATIONAHA.107.185734","article-title":"AACVPR\/ACC AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation\/secondary prevention services","volume":"116","author":"Thomas","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.04.019_bib24","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ihj.2013.04.019_bib25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ypmed.2010.08.014","article-title":"Cardiovascular risk according to educational status in India","volume":"51","author":"Gupta","year":"2010","journal-title":"Prev Med"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483213001090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483213001090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:48:37Z","timestamp":1758080917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483213001090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0019483213001090"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2013.04.019","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology of cardioprotective pharmacological agent use in stable coronary heart disease","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2013.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}